Drug Shortage Active
DURAMORPH PF is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
DURAMORPH PF is a preservative-free injectable morphine sulfate solution approved in 1984 for parenteral opioid analgesia in acute and chronic pain settings. It is a small-molecule opioid agonist that binds mu receptors in the central nervous system to produce analgesia, sedation, and euphoria. The product is primarily used in hospital settings for perioperative pain management and cancer pain.
With LOE approaching and moderate competitive pressure, the brand team is likely focused on defending market share in institutional channels rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
DURAMORPH PF offers limited career growth opportunities given its LOE-approaching status, active supply shortage, and absence of linked job postings. Roles on this product would focus on defensive commercial strategies, formulary management, and supply chain problem-solving rather than growth or innovation.
Worked on DURAMORPH PF at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo